FATE THERAPEUTICS INC (FATE)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $95k
- Aug 4 · Unusual
- Form 4 sales
- 140
- On record
- Form 144 notices
- 16
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planAug 4 2025
Sold 14,466 shares at $1.06 ($15k)
Valamehr Bahram, President and CEO
No 10b5-1 planSold 4.1% of holdings ($370k position)334,898 shares leftFiling
- 2 Form 4 saleNo planAug 4 same day
Sold 9,037 shares at $1.06 ($10k)
Tahl Cindy, Officer
No 10b5-1 planSold 2.2% of holdings ($431k position)397,670 shares left0.8x usual sizeFiling
- 3 Form 4 saleNo planJan 9 +158 days
Sold 5,190 shares at $1.07 ($6k)
Valamehr Bahram, President and CEO
No 10b5-1 planSold 1.5% of holdings ($358k position)329,708 shares leftFiling
- 4 Form 4 saleNo planJan 9 same day
Sold 10,589 shares at $1.06 ($11k)
Tahl Cindy, Officer
No 10b5-1 planSold 2.7% of holdings ($422k position)387,081 shares leftFiling
- 5 Form 4 saleUnusualMay 20 +131 days
Sold 28,946 shares at $1.88 ($54k)
Valamehr Bahram, President and CEO
No 10b5-1 planSold 4.4% of holdings ($1.2M position)635,762 shares left3.3x usual sizeFiling
- 6 Form 4 saleNo planMay 20 same day
Sold 25,590 shares at $1.88 ($48k)
Tahl Cindy, Officer
No 10b5-1 planSold 3.9% of holdings ($1.2M position)628,155 shares left2.8x usual sizeFiling
- 7 Form 4 saleUnusualAug 4 +76 days
Sold 43,947 shares at $2.46 ($108k)
Valamehr Bahram, President and CEO
No 10b5-1 planSold 6.9% of holdings ($1.6M position)591,815 shares left3.8x usual sizeFiling
- 8 Form 4 saleUnusualAug 4 same day
Sold 38,800 shares at $2.46 ($95k)
Tahl Cindy, Officer
No 10b5-1 planSold 6.2% of holdings ($1.5M position)589,355 shares left4x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (156)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Tahl Cindy | Officer | Form 4 sale | 38,800 | $95k | 6.2% | Unusual | SEC |
| Aug 4, 2026 | Valamehr Bahram | President and CEO | Form 4 sale | 43,947 | $108k | 6.9% | Unusual | SEC |
| May 20, 2026 | Tahl Cindy | Officer | Form 4 sale | 25,590 | $48k | 3.9% | No plan | SEC |
| May 20, 2026 | Valamehr Bahram | President and CEO | Form 4 sale | 28,946 | $54k | 4.4% | Unusual | SEC |
| Jan 9, 2026 | Tahl Cindy | Officer | Form 4 sale | 10,589 | $11k | 2.7% | No plan | SEC |
| Jan 9, 2026 | Valamehr Bahram | President and CEO | Form 4 sale | 5,190 | $6k | 1.5% | No plan | SEC |
| Aug 4, 2025 | Tahl Cindy | Officer | Form 4 sale | 9,037 | $10k | 2.2% | No plan | SEC |
| Aug 4, 2025 | Valamehr Bahram | President and CEO | Form 4 sale | 14,466 | $15k | 4.1% | No plan | SEC |
| Jan 10, 2025 | Bressi Jerome Charles | Officer | Form 4 sale | 5,980 | $9k | 2.2% | No plan | SEC |
| Jan 10, 2025 | Tahl Cindy | Officer | Form 4 sale | 5,654 | $9k | 1.7% | No plan | SEC |
| Jan 10, 2025 | Valamehr Bahram | President and CEO | Form 4 sale | 8,705 | $13k | 2.4% | No plan | SEC |
| Dec 20, 2024 | Green Jeremy | Director, 10% owner | Form 4 sale | 341,633 | $574k | 2.7% | No plan | SEC |
| Dec 20, 2024 | Redmile Group, LLC | Director, 10% Stockholder | Form 144 notice | 341,633 | $567k | Notice | SEC | |
| Aug 6, 2024 | Xu Yuan | Director | Form 4 sale | 633 | $3k | 6.8% | Routine | SEC |
| Mar 4, 2024 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 2,447 | $19k | 2.4% | Routine | SEC |
| Jan 29, 2024 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 1,849 | $9k | 1.7% | Routine | SEC |
| Jan 29, 2024 | Dulac Edward J III | Officer | Form 144 notice | 1,849 | $9k | Notice | SEC | |
| Jan 9, 2024 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 10,874 | $48k | 7.1% | No plan | SEC |
| Jan 9, 2024 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 11,271 | $49k | 6.7% | No plan | SEC |
| Jan 9, 2024 | Wolchko J Scott | President and CEO | Form 4 sale | 14,391 | $63k | 3.7% | No plan | SEC |
| Jan 9, 2024 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 7,028 | $31k | 6.2% | No plan | SEC |
| Jan 9, 2024 | Wolchko J Scott | Officer, Director | Form 144 notice | 14,391 | $63k | Notice | SEC | |
| Jan 9, 2024 | Dulac Edward J III | Officer | Form 144 notice | 7,028 | $31k | Notice | SEC | |
| Jan 9, 2024 | Tahl Cindy | Officer | Form 144 notice | 10,874 | $47k | Notice | SEC | |
| Jan 9, 2024 | Valamehr Bahram | Officer | Form 144 notice | 11,271 | $49k | Notice | SEC | |
| Jan 2, 2024 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 5,182 | $19k | 4.4% | Routine | SEC |
| Jan 2, 2024 | Dulac Edward J III | Officer | Form 144 notice | 5,182 | $19k | Notice | SEC | |
| Dec 18, 2023 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 1,585 | $6k | 1.3% | Routine | SEC |
| Dec 18, 2023 | Dulac Edward J III | Officer | Form 144 notice | 1,585 | $6k | Notice | SEC | |
| Nov 9, 2023 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 24,363 | $58k | 13.7% | Routine | SEC |
| Nov 9, 2023 | Tahl Cindy | Officer | Form 144 notice | 24,363 | $58k | Notice | SEC | |
| Aug 18, 2023 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 4,718 | $13k | 3.8% | No plan | SEC |
| Aug 18, 2023 | Dulac Edward J III | Officer | Form 144 notice | 4,718 | $13k | Notice | SEC | |
| Aug 4, 2023 | Xu Yuan | Director | Form 4 sale | 632 | $2k | 6.4% | Routine | SEC |
| Aug 4, 2023 | Xu Yuan | Director | Form 144 notice | 632 | $2k | Notice | SEC | |
| Jul 5, 2023 | Powl Brian T. | Chief Commercial Officer | Form 4 sale | 3,854 | $19k | 8.6% | No plan | SEC |
| Jul 5, 2023 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 5,182 | $25k | 4.0% | Routine | SEC |
| Jul 5, 2023 | Powl Brian T. | Officer | Form 144 notice | 3,854 | $19k | Notice | SEC | |
| Jul 5, 2023 | Dulac Edward J III | Officer | Form 144 notice | 5,182 | $25k | Notice | SEC | |
| Jun 14, 2023 | Xu Yuan | Director | Form 4 sale | 3,460 | $19k | 25.8% | Routine | SEC |
| Jun 14, 2023 | Xu Yuan | Director | Form 144 notice | 3,460 | $19k | Notice | SEC | |
| Apr 18, 2023 | Chu Yu-Waye | Chief Medical Officer | Form 4 sale | 2,532 | $17k | 1.8% | Routine | SEC |
| Apr 18, 2023 | Chu Yu-Waye | Officer | Form 144 notice | 2,532 | $17k | Notice | SEC | |
| Apr 14, 2023 | Green Jeremy | Director, 10% owner | Form 4 sale | 302,339 | $1.8M | 2.3% | No plan | SEC |
| Apr 14, 2023 | Redmile Capital Offshore Fund (ERISA), Ltd. | Director,10% Stockholder | Form 144 notice | 135,134 | $758k | Notice | SEC | |
| Jan 10, 2023 | Wolchko J Scott | President and CEO | Form 4 sale | 45,907 | $241k | 10.6% | Plan not stated | SEC |
| Jan 10, 2023 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 10,917 | $57k | 6.1% | Plan not stated | SEC |
| Jan 10, 2023 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 11,553 | $61k | 6.1% | Plan not stated | SEC |
| Jan 10, 2023 | Plavsic Mark | Chief Technical Officer | Form 4 sale | 3,418 | $18k | 2.7% | Plan not stated | SEC |
| Jan 10, 2023 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 7,331 | $38k | 5.4% | Plan not stated | SEC |
| Jan 10, 2023 | Chu Yu-Waye | Chief Medical Officer | Form 4 sale | 7,825 | $41k | 5.2% | Plan not stated | SEC |
| Aug 18, 2022 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 5,135 | $153k | 3.6% | Plan not stated | SEC |
| Jul 22, 2022 | Wolchko J Scott | President and CEO | Form 4 sale | 36,246 | $1.2M | 7.7% | Plan not stated | SEC |
| Jul 7, 2022 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 17,158 | $519k | 8.7% | Plan not stated | SEC |
| Jul 6, 2022 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 7,842 | $236k | 4.2% | Plan not stated | SEC |
| Jul 5, 2022 | Plavsic Mark | Chief Technical Officer | Form 4 sale | 3,719 | $92k | 2.8% | Plan not stated | SEC |
| Jun 7, 2022 | Agarwal Shefali | Director | Form 4 sale | 841 | $18k | 31.4% | Unusual | SEC |
| Jun 3, 2022 | Mendlein John | Director | Form 4 sale | 1,364 | $31k | 0.9% | Plan not stated | SEC |
| Jun 3, 2022 | Jooss Karin | Director | Form 4 sale | 1,483 | $34k | 55.3% | Unusual | SEC |
| Jun 3, 2022 | Hershberg Robert | Director | Form 4 sale | 672 | $15k | 25.1% | Unusual | SEC |
| Jun 3, 2022 | Coughlin Timothy | Director | Form 4 sale | 1,439 | $33k | 2.4% | Plan not stated | SEC |
| Jun 3, 2022 | Agarwal Shefali | Director | Form 4 sale | 807 | $18k | 30.1% | Unusual | SEC |
| Jun 1, 2022 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 25,000 | $574k | 11.7% | Plan not stated | SEC |
| Apr 22, 2022 | Wolchko J Scott | President and CEO | Form 4 sale | 40,000 | $1.4M | 8.5% | Plan not stated | SEC |
| Apr 19, 2022 | Chu Yu-Waye | Chief Medical Officer | Form 4 sale | 4,062 | $144k | 2.6% | Plan not stated | SEC |
| Apr 1, 2022 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 25,000 | $971k | 11.7% | Plan not stated | SEC |
| Mar 14, 2022 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 25,000 | $777k | 12.2% | Plan not stated | SEC |
| Mar 10, 2022 | Mendlein John | Director | Form 4 sale | 31,562 | $1.1M | 16.5% | Plan not stated | SEC |
| Jan 21, 2022 | Wolchko J Scott | President and CEO | Form 4 sale | 40,000 | $1.6M | 8.5% | Plan not stated | SEC |
| Jan 11, 2022 | Wolchko J Scott | President and CEO | Form 4 sale | 14,566 | $709k | 3.3% | Plan not stated | SEC |
| Jan 11, 2022 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 5,419 | $263k | 3.4% | Plan not stated | SEC |
| Jan 11, 2022 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 4,570 | $222k | 3.0% | Plan not stated | SEC |
| Jan 11, 2022 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 1,770 | $86k | 1.6% | Plan not stated | SEC |
| Jan 11, 2022 | Chu Yu-Waye | Senior VP Clinical Development | Form 4 sale | 3,965 | $192k | 3.2% | Plan not stated | SEC |
| Jan 10, 2022 | Wolchko J Scott | President and CEO | Form 4 sale | 34,156 | $1.6M | 7.1% | Plan not stated | SEC |
| Jan 10, 2022 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 7,738 | $359k | 4.6% | Plan not stated | SEC |
| Jan 10, 2022 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 5,596 | $260k | 3.6% | Plan not stated | SEC |
| Jan 3, 2022 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 50,000 | $3M | 22.8% | Plan not stated | SEC |
| Dec 20, 2021 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 15,977 | $959k | 12.6% | Plan not stated | SEC |
| Dec 13, 2021 | Valamehr Bahram | Chief R&D Officer | Form 4 sale | 25,000 | $1.2M | 13.8% | Plan not stated | SEC |
| Dec 10, 2021 | Chu Yu-Waye | Senior VP Clinical Development | Form 4 sale | 7,500 | $386k | 5.6% | Plan not stated | SEC |
| Nov 18, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $1.1M | 4.8% | Plan not stated | SEC |
| Oct 22, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 60,000 | $3.6M | 13.2% | Plan not stated | SEC |
| Oct 1, 2021 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 50,000 | $2.9M | 31.6% | Unusual | SEC |
| Sep 28, 2021 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 19,460 | $1.2M | 27.1% | Unusual | SEC |
| Sep 13, 2021 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 25,000 | $1.7M | 20.7% | Plan not stated | SEC |
| Aug 19, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $1.8M | 4.8% | Plan not stated | SEC |
| Aug 19, 2021 | Dulac Edward J III | Chief Financial Officer | Form 4 sale | 3,474 | $307k | 6.0% | Plan not stated | SEC |
| Jul 23, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 60,000 | $5.1M | 13.2% | Plan not stated | SEC |
| Jul 1, 2021 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 55,534 | $4.7M | 33.9% | Unusual | SEC |
| Jun 14, 2021 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 25,000 | $2.2M | 20.7% | Plan not stated | SEC |
| May 20, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $1.5M | 4.8% | Plan not stated | SEC |
| Apr 23, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 60,000 | $5.1M | 13.2% | Plan not stated | SEC |
| Apr 16, 2021 | Chu Yu-Waye | Senior VP Clinical Development | Form 4 sale | 3,275 | $273k | 4.8% | Plan not stated | SEC |
| Apr 1, 2021 | Tahl Cindy | Officer | Form 4 sale | 30,000 | $2.5M | 21.7% | Plan not stated | SEC |
| Mar 15, 2021 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 25,000 | $2.3M | 20.7% | Plan not stated | SEC |
| Mar 8, 2021 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 25,000 | $2M | 25.5% | Unusual | SEC |
| Feb 18, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $2M | 4.8% | Plan not stated | SEC |
| Jan 22, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 60,000 | $6M | 13.2% | Plan not stated | SEC |
| Jan 19, 2021 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 35,000 | $4M | 28.0% | Unusual | SEC |
| Jan 11, 2021 | Wolchko J Scott | President and CEO | Form 4 sale | 69,407 | $8.1M | 16.5% | Unusual | SEC |
| Jan 11, 2021 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 9,484 | $1.1M | 10.9% | Plan not stated | SEC |
| Jan 11, 2021 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 9,483 | $1.1M | 9.5% | Plan not stated | SEC |
| Jan 11, 2021 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 9,482 | $1.1M | 10.2% | Plan not stated | SEC |
| Dec 17, 2020 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $1.8M | 4.5% | Plan not stated | SEC |
| Dec 14, 2020 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 25,000 | $2.4M | 22.3% | Unusual | SEC |
| Nov 16, 2020 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 25,000 | $1.3M | 21.2% | Plan not stated | SEC |
| Nov 13, 2020 | Wolchko J Scott | President and CEO | Form 4 sale | 60,000 | $3.1M | 12.5% | Plan not stated | SEC |
| Nov 5, 2020 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 70,801 | $3.6M | 41.6% | Unusual | SEC |
| Oct 16, 2020 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 29,199 | $1.5M | 22.7% | Plan not stated | SEC |
| Oct 1, 2020 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 35,000 | $1.4M | 26.0% | Unusual | SEC |
| Sep 14, 2020 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 25,000 | $907k | 22.3% | Plan not stated | SEC |
| Sep 14, 2020 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 25,000 | $908k | 17.5% | Plan not stated | SEC |
| Jan 30, 2020 | Wolchko J Scott | President and CEO | Form 4 sale | 25,000 | $636k | 5.6% | Plan not stated | SEC |
| Jan 8, 2020 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 5,700 | $118k | 6.2% | Plan not stated | SEC |
| Jan 8, 2020 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 5,700 | $118k | 5.4% | Plan not stated | SEC |
| Jan 8, 2020 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 5,700 | $118k | 3.8% | Plan not stated | SEC |
| Dec 30, 2019 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 25,000 | $487k | 16.8% | Plan not stated | SEC |
| Dec 20, 2019 | Wolchko J Scott | President and CEO | Form 4 sale | 50,000 | $1M | 12.4% | Plan not stated | SEC |
| Oct 15, 2019 | Wolchko J Scott | President and CEO | Form 4 sale | 21,017 | $303k | 5.6% | Plan not stated | SEC |
| Oct 15, 2019 | Valamehr Bahram | Chief Development Officer | Form 4 sale | 6,200 | $88k | 8.5% | Plan not stated | SEC |
| Oct 15, 2019 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 10,200 | $145k | 11.3% | Plan not stated | SEC |
| Oct 15, 2019 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 11,800 | $169k | 8.7% | Plan not stated | SEC |
| Aug 1, 2019 | Nashat Amir | Director | Form 4 sale | 62,005 | $1.4M | 84.9% | Unusual | SEC |
| Jul 30, 2019 | Nashat Amir | Director | Form 4 sale | 118,333 | $2.7M | 91.0% | Unusual | SEC |
| Jul 24, 2019 | Nashat Amir | Director | Form 4 sale | 81,899 | $1.8M | 86.5% | Unusual | SEC |
| Jul 22, 2019 | Nashat Amir | Director | Form 4 sale | 71,166 | $1.6M | 84.0% | Unusual | SEC |
| Jun 27, 2019 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 12,500 | $253k | 8.4% | Plan not stated | SEC |
| May 16, 2019 | Wolchko J Scott | President and CEO | Form 4 sale | 14,335 | $278k | 3.7% | Plan not stated | SEC |
| Apr 18, 2019 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $322k | 5.1% | Plan not stated | SEC |
| Mar 28, 2019 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 12,500 | $212k | 8.4% | Plan not stated | SEC |
| Mar 21, 2019 | Wolchko J Scott | President and CEO | Form 4 sale | 20,000 | $352k | 5.1% | Plan not stated | SEC |
| Mar 1, 2019 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 25,000 | $404k | 21.7% | Plan not stated | SEC |
| Feb 25, 2019 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 25,000 | $402k | 21.7% | Plan not stated | SEC |
| Jan 30, 2019 | Nashat Amir | Director | Form 4 sale | 53,017 | $751k | 3.5% | Plan not stated | SEC |
| Jan 29, 2019 | Nashat Amir | Director | Form 4 sale | 97,500 | $1.4M | 6.0% | Plan not stated | SEC |
| Jan 28, 2019 | Nashat Amir | Director | Form 4 sale | 70,000 | $965k | 4.1% | Plan not stated | SEC |
| Jan 25, 2019 | Nashat Amir | Director | Form 4 sale | 90,000 | $1.3M | 5.0% | Plan not stated | SEC |
| Jan 18, 2019 | Nashat Amir | Director | Form 4 sale | 39,483 | $643k | 2.2% | Plan not stated | SEC |
| Jan 7, 2019 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 25,000 | $400k | 35.5% | Unusual | SEC |
| Dec 20, 2018 | Nashat Amir | Director | Form 4 sale | 33,474 | $410k | 1.8% | Plan not stated | SEC |
| Dec 19, 2018 | Nashat Amir | Director | Form 4 sale | 91,210 | $1.2M | 4.7% | Plan not stated | SEC |
| Dec 13, 2018 | Nashat Amir | Director | Form 4 sale | 17,788 | $297k | 0.9% | Plan not stated | SEC |
| Dec 12, 2018 | Nashat Amir | Director | Form 4 sale | 425,000 | $7.1M | 17.8% | Plan not stated | SEC |
| Dec 11, 2018 | Nashat Amir | Director | Form 4 sale | 82,528 | $1.4M | 3.3% | Plan not stated | SEC |
| Oct 16, 2017 | Wolchko J Scott | President and CEO | Form 4 sale | 17,168 | $67k | 12.1% | Plan not stated | SEC |
| Oct 16, 2017 | Tahl Cindy | General Counsel and Secretary | Form 4 sale | 8,091 | $31k | 15.1% | Plan not stated | SEC |
| Oct 16, 2017 | Shoemaker Daniel D | Chief Scientific Officer | Form 4 sale | 13,225 | $51k | 12.7% | Plan not stated | SEC |
| Jun 12, 2014 | Flynn Peter D | Officer | Form 4 sale | 6,488 | $45k | 61.6% | Unusual | SEC |
| Jun 10, 2014 | Flynn Peter D | Officer | Form 4 sale | 3,305 | $23k | 45.0% | Unusual | SEC |
| May 1, 2014 | Flynn Peter D | Officer | Form 4 sale | 9,793 | $69k | 64.5% | Unusual | SEC |
| Apr 4, 2014 | Flynn Peter D | Officer | Form 4 sale | 5,889 | $47k | 46.7% | Unusual | SEC |
| Apr 2, 2014 | Weyer Christian | Officer, Director | Form 4 sale | 10,000 | $90k | 100.0% | Unusual | SEC |
| Apr 1, 2014 | Flynn Peter D | Officer | Form 4 sale | 4,038 | $40k | 37.5% | Unusual | SEC |
| Apr 1, 2014 | Wolchko J Scott | Officer | Form 4 sale | 20,000 | $193k | 57.1% | Unusual | SEC |
| Mar 31, 2014 | Shoemaker Daniel D | Chief Technology Officer | Form 4 sale | 8,653 | $85k | 25.0% | Plan not stated | SEC |